GlassScriptPhysician profile
Rita L All
NPI 1003222159
$2,391.38
in general payments reported to CMS, 2019-2025
15 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $669 · 2023: $891 · 2024: $452 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $461.81 | 2022-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $250.25 | 2022-2023 | |
| Boston Scientific Corporation | $218.88 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Lilly USA, LLC | $204.06 | 2024 | Zepbound |
| Sanofi-Aventis U.S. LLC | $183.18 | 2021-2023 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $119.93 | 2023 | Crysvita |
| Neurocrine Biosciences, INC. | $118.02 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $117.21 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $114.60 | 2022 | |
| Horizon Therapeutics Plc | $114.30 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $107.40 | 2024 | Auvelity |
| Jazz Pharmaceuticals INC. | $95.95 | 2022 | |
| Medtronic, INC. | $81.35 | 2022 | |
| Neurelis, INC. | $79.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita All listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.